Literature DB >> 25083826

Community outcome in cognitively normal schizophrenia patients.

Eva Muharib1, R Walter Heinrichs1, Ashley Miles1, Farena Pinnock1, Stephanie McDermid Vaz2, Narmeen Ammari1.   

Abstract

Recent reports suggest that cognition is relatively preserved in some schizophrenia patients. However, little is known about the functional advantage these patients may demonstrate. The purpose of this study was to identify cognitively normal patients with a recently developed test battery and to determine the functional benefit of this normality relative to cognitively impaired patients. Average-range cognitive ability was defined by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) composite score (T≥40) and applied to 100 patients with schizophrenia or schizoaffective disorder and to 81 non-psychiatric research participants. With group assignment adjusted for demographic variables, this procedure yielded 14 cognitively normal patients, 21 cognitively impaired patients, and 21 healthy adults with normal-range MCCB scores. Cognitively normal patients were indistinguishable from controls across all MCCB scales. Furthermore, their performance was superior to impaired patients on all scales except Social Cognition. Cognitively normal patients were also superior to impaired patients on a summary index of simulated life skills and functional competence. Nevertheless, both patient groups were equally disadvantaged relative to controls in independent community living. These findings suggest that normal-range cognition exists in schizophrenia, but fails to translate into enhanced community outcome.

Entities:  

Mesh:

Year:  2014        PMID: 25083826     DOI: 10.1017/S1355617714000629

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  5 in total

1.  Resting-State Connectivity Biomarkers of Cognitive Performance and Social Function in Individuals With Schizophrenia Spectrum Disorder and Healthy Control Subjects.

Authors:  Joseph D Viviano; Robert W Buchanan; Navona Calarco; James M Gold; George Foussias; Nikhil Bhagwat; Laura Stefanik; Colin Hawco; Pamela DeRosse; Miklos Argyelan; Jessica Turner; Sofia Chavez; Peter Kochunov; Peter Kingsley; Xiangzhi Zhou; Anil K Malhotra; Aristotle N Voineskos
Journal:  Biol Psychiatry       Date:  2018-04-13       Impact factor: 13.382

2.  Validation of the cognitively normal range and below normal range subtypes in chronically hospitalized patients with schizophrenia.

Authors:  Shih-Kuang Chiang; Ching-Huan Ni; Chih-Pu Tsai; Keng-Chang Lin
Journal:  Schizophr Res Cogn       Date:  2016-07-13

3.  Cortical Thinning in Network-Associated Regions in Cognitively Normal and Below-Normal Range Schizophrenia.

Authors:  R Walter Heinrichs; Farena Pinnock; Melissa Parlar; Colin Hawco; Lindsay Hanford; Geoffrey B Hall
Journal:  Schizophr Res Treatment       Date:  2017-02-28

4.  Neurocognitive normality in schizophrenia revisited.

Authors:  R Walter Heinrichs; Farena Pinnock; Eva Muharib; Leah Hartman; Joel Goldberg; Stephanie McDermid Vaz
Journal:  Schizophr Res Cogn       Date:  2015-11-19

Review 5.  Assessing the Relationship between Performance on the University of California Performance Skills Assessment (UPSA) and Outcomes in Schizophrenia: A Systematic Review and Evidence Synthesis.

Authors:  Shelagh Szabo; Elizabeth Merikle; Greta Lozano-Ortega; Lauren Powell; Thomas Macek; Stephanie Cline
Journal:  Schizophr Res Treatment       Date:  2018-12-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.